Does high sensitive CRP improve cardiovascular risk prediction in metabolic syndrome among the aged?
Marika Salminen1, Marikka Kuoppamäki, Tero Vahlberg
1Institute of Clinical Medicine, Family Medicine, FI-20014 University of Turku, Turku, Finland. majosa@utu.fi
Insights
High-sensitivity C-reactive protein (hsCRP) does not add value in predicting cardiovascular events or mortality in older adults with metabolic syndrome (MetS). This study found no significant interaction between hsCRP levels and MetS for these outcomes.
Area of Science:
- Gerontology
- Cardiology
- Biomarkers
Background:
- Metabolic syndrome (MetS) is a cluster of conditions increasing cardiovascular disease (CVD) risk.
- High-sensitivity C-reactive protein (hsCRP) is an inflammatory marker associated with CVD.
- The additive prognostic value of hsCRP in older adults with MetS requires further investigation.
Purpose of the Study:
- To determine if elevated hsCRP levels provide additional predictive value for cardiovascular events (CVEs) and all-cause mortality in elderly individuals with MetS.
- To analyze the interaction between hsCRP and MetS in predicting future cardiovascular events and mortality in the aged population.
Main Methods:
- A prospective, population-based study followed 733 individuals aged 64+ for 9 years.
- Participants were free of vascular disease and had CRP < 10 mg/l at baseline.
- Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for CVEs and all-cause mortality, considering MetS (IDF and WHO definitions) and hsCRP levels.
Main Results:
- Over 9 years, 142 CVEs and 206 deaths occurred.
- No significant interaction was found between hsCRP and MetS for CVEs or all-cause mortality (p > 0.05 for all interaction tests).
- hsCRP alone was not significantly associated with CVEs or all-cause mortality in this cohort.
Conclusions:
- Elevated hsCRP does not appear to offer additional predictive value for cardiovascular events or all-cause mortality in older subjects already diagnosed with metabolic syndrome.
- Current inflammatory markers like hsCRP may not enhance risk stratification beyond MetS criteria in the elderly.
Objectives:
To analyze whether an elevated level of high hsCRP has an additive effect on metabolic syndrome (MetS) in predicting future cardiovascular events (CVEs) as well as on all-cause mortality among the aged subjects.
Design:
A prospective, population-based study with a 9-year follow-up. The study population consisted of persons aged 64 and above in 1998-99 without vascular disease and CRP less than 10 mg/l at baseline (n = 733). Adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) for CVEs and all-cause mortality predicted by baseline MetS (defined by both International Diabetes Federation (IDF) and World Health Organization (WHO)) and hsCRP-level were estimated.
Results:
During the 9-year follow-up, a total of 142 CVEs and 206 deaths occurred. After multivariable adjustment, no significant interactions were found between hsCRP and MetS in CVEs (IDF: p = 0.828; WHO: p = 0.572) or in all-cause mortality (IDF: p = 0.113; WHO: p = 0.374). HsCRP was not associated with the occurrence of CVEs (IDF: HR = 1.10, 95% CI = 0.92-1.32, p = 0.281; WHO: HR = 1.10, 95% CI = 0.93-1.32, p = 0.247) or with all-cause mortality (IDF: HR = 1.12, 95% CI = 0.97-1.29, p = 0.134; WHO: HR = 1.11, 95% CI = 0.96-1.28, p = 0.146).
Conclusions:
It seems that hsCRP does not give any extra value in evaluation of CVE risk or all-cause mortality of older subjects with MetS.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Atherosclerosis III: Management
Acute Coronary Syndrome III: Diagnostic Studies
